There are currently four categories of US Food and Drug Administration (FDA)-approved biological drugs for use in psoriasis: tumor necrosis factor inhibitors (TNFi) (etanercept, infliximab, adalimumab, and certolizumab); interleukin IL-12/23 antagonists (ustekinumab); IL-17A inhibitors (secukinumab and ixekizumab); and anti-IL-23 agents (tildrakizumab, risankizumab, and guselkumab) [59]. Here, IL17A is linked to psoriasis.